Journal of Biomedical Advancement Scientific Research

Abstract

Sarcopenia and osteoporosis frequently coexist in older adults as osteosarcopenia, a high-risk phenotype associated with falls, fractures, disability, and mortality. Palm tocotrienol-rich fraction (TRF) has emerged as a potential multi-target geroscience intervention because tocotrienols influence redox homeostasis, inflammatory signaling, cellular senescence, mitochondrial function, and musculoskeletal metabolism. This qualitative literature review critically synthesizes contemporary evidence concerning TRF and related tocotrienol interventions across aging skeletal muscle, bone remodeling, and bone–muscle crosstalk. Cellular studies indicate that TRF can improve the regenerative phenotype of senescent human myoblasts. Aging-animal metabolomics demonstrates modulation of amino-acid, carnitine, and energy-related pathways, while recent γ-tocotrienol studies show suppression of MuRF-1 and Atrogin-1, preservation of mitochondrial function, and improved muscle strength in inflammatory atrophy models. Tocotrienols also exert skeletal effects involving osteoblasts, osteoclasts, osteocytes, Wnt-related signaling, RANKL/OPG, and sclerostin. However, direct human evidence for sarcopenia or osteosarcopenia remains inadequate. The major translational challenge is therefore to determine whether molecular and metabolomic effects translate into improvements in muscle strength, physical performance, appendicular lean mass, bone mineral density, falls, and fracture risk. A precision-geroscience trial framework combining standardized palm TRF with resistance exercise and integrated musculoskeletal and multi-omics endpoints is proposed.